Actively Recruiting
RESOLVE Open-label Phase 4 Study to Evaluate Safety, Tolerability, and Neuropsychiatric Effects of Zunveyl in Adults with Mild to Moderate Alzheimers Disease
Led by Alpha Cognition, Inc · Updated on 2026-10-19
150
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial is focused on adults aged 50 and older with mild to moderate Alzheimers disease. Researchers aim to evaluate the safety and tolerability of Zunveyl, a medication taken orally, during 12 weeks of routine use. The study also looks at how the drug affects neuropsychiatric symptoms and caregiver distress for these patients. Participants will take Zunveyl delayed-release tablets twice daily, starting with 5 mg from Weeks 1 to 4, then increasing to 10 mg twice daily from Weeks 5 to 12. This open-label, phase 4 study monitors participants throughout this 12-week treatment period to assess how well they tolerate the medication and to observe any side effects. During the study, participants and their caregivers will attend regular visits where assessments will be made including safety checks, neuropsychiatric evaluations using the Neuropsychiatric Inventory NPI-12, and measurements of caregiver distress. Researchers will track adverse events, treatment interruptions, dose reductions, and overall tolerability scores up to Week 17. The total participation lasts about 12 weeks with follow-up assessments to evaluate ongoing safety and effects.
CONDITIONS
Brief Title
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
Research Team
K
Kurt P Grady, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here